echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: BCMA targeted CAR-T cell therapy Idecabtagene Vicleucel (Ide-cel) achieved positive results

    NEJM: BCMA targeted CAR-T cell therapy Idecabtagene Vicleucel (Ide-cel) achieved positive results

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The Phase II KarMMa trial evaluated the efficacy and safety of CAR-T cell therapy targeted by the B cell maturation antigen (BCMA) of bluebird bio and Bristol Myers Squibb .


    CAR-T immunity

    The KarMMa study reached the primary endpoint of overall response rate and the key secondary endpoint of complete response rate.


    The data showed that triple-exposed RRMM patients (n = 128) received ide-cel treatment to produce a deep and long-lasting response.


    In the KarMMa study, ide-cel is consistent with the known toxicity of CAR-T cell therapy, regardless of the dose level.


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.